PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.2888
https://www.valueinhealthjournal.com/article/S1098-3015(18)36263-6/fulltext
Section Title :
Section Order :
1076
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)36263-6&doi=10.1016/j.jval.2018.09.2888